Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
暂无分享,去创建一个
Thierry Gil | Camilla Thellenberg Karlsson | I. Tannock | B. Tombal | G. Gravis | T. Gil | T. Elliott | A. Birtle | K. Fizazi | I. Skoneczna | M. Rosenthal | C. Karlsson | O. Aren | F. Orlandi | Karim Fizazi | Bertrand Tombal | E. Magherini | Ian F. Tannock | Gwenaelle Gravis | Sergey Ivanov | Aude Flechon | Iwona Skoneczna | Francisco F. Orlandi | Vsevolod V. Matveev | Sevil S. Bavbek | Luciano L. Viana | Osvaldo O. Arén | Oleg Karyakin | Tony Elliott | Alison A. Birtle | Emmanuelle E. Magherini | Laurence L. Hatteville | Daniel D. Petrylak | M. Rosenthal | D. Petrylak | S. Bavbek | L. Viana | L. Hatteville | V. Matveev | O. Karyakin | A. Flechon | S. Ivanov
[1] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Fumoleau,et al. Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[3] Lisa Wang,et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Albers,et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Harris,et al. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. , 2010, The Lancet. Oncology.
[6] P. Philip,et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. , 2013, European journal of cancer.
[7] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[8] G. Thurston,et al. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors , 2010, Cancer biology & therapy.
[9] P. Kantoff,et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Sosman,et al. Combination targeted therapy in advanced renal cell carcinoma , 2009, Cancer.
[11] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[12] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Moore,et al. Treatment of hormone refractory prostate cancer. , 2001, Seminars in urologic oncology.
[14] F. Saad,et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T R Fleming,et al. Designs for group sequential tests. , 1984, Controlled clinical trials.
[16] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Scagliotti,et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Sternberg,et al. A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) with or without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The Mainsail Trial , 2012 .
[19] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[20] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[21] I. Tannock,et al. From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Gleave,et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] I. Thompson,et al. SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). , 2012 .
[25] K. Pienta,et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.
[26] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[27] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[28] M. Gleave,et al. Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone , 2012, Cancer.
[29] C. Ng,et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. , 2011, The Lancet. Oncology.
[30] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[31] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.